Diurnal Group (LON:DNL) Posts Earnings Results, Beats Estimates By $2.40 EPS

Diurnal Group (LON:DNL) posted its quarterly earnings results on Tuesday. The company reported GBX (4.30) (($0.06)) earnings per share for the quarter, beating the Zacks’ consensus estimate of GBX (6.70) (($0.09)) by GBX 2.40 ($0.03), Digital Look Earnings reports.

DNL stock opened at GBX 59 ($0.77) on Wednesday. The business’s fifty day moving average is GBX 52.08 and its 200-day moving average is GBX 36.72. The company has a quick ratio of 3.80, a current ratio of 4.46 and a debt-to-equity ratio of 0.77. The company has a market cap of $71.99 million and a P/E ratio of -5.23. Diurnal Group has a twelve month low of GBX 19 ($0.25) and a twelve month high of GBX 69 ($0.90).

In related news, insider Richard Bungay sold 41,873 shares of the firm’s stock in a transaction on Wednesday, July 15th. The stock was sold at an average price of GBX 30 ($0.39), for a total transaction of £12,561.90 ($16,414.35).

Diurnal Group Company Profile

Diurnal Group plc operates as a specialty pharma company. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Its product pipeline includes Infacort for use in children suffering from adrenal insufficiency; and Chronocort, which completed Phase III clinical trials targeting congenital adrenal hyperplasia in adult patients, as well as adrenal insufficiency.

Read More: The components of the Stochastic Momentum Index

Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with MarketBeat.com's FREE daily email newsletter.